Dr Launay-Vacher is the author of a number of publications mainly in indexed international journals (150), on drug pharmacokinetics and renal effects, and prevalence of kidney disease in cancer. His clinical research activities have focused on the study of drugs’ pharmacokinetics and dosage adjustment in patients with renal insufficiency. He coordinated several National studies, among which the “IRMA” studies (1 and 2) (Renal Insufficiency and Anticancer Medications) on the prevalence of renal insufficiency in French cancer patients, dosage adjustment of anticancer drugs, and impact on survival. These studies included near 5000 patients each and demonstrated the high prevalence of impaired renal function in cancer patients and the consequences on anticancer drugs handling regarding their potential toxicity and their dosages in such patients. The results of “IRMA” have been presented as oral communications at several international conferences in Oncology. Dr Launay-Vacher is member of the French Society of Nephrology, the International Society of Geriatric Oncology (SIOG), the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), and the French-speaking Association for Supportive Care in Cancer (AFSOS). He also collaborates on the Task Force on Renal Insufficiency and Safety in the Elderly Cancer Patient of the SIOG, the Task Force in the Elderly of the EORTC (European Organization for Research and Treatment of Cancer), and he is founding member of the Cancer & the Kidney International Network (C-KIN).

 Nephrology